Chr 11 FISH-mapped BACs from CGAP There is no FDA-approved treatment. However, recent research indicates that mild to moderate dietary restrictions slow the progression of autosomal dominant<unk>  (ADPKD) in mice. If and when the disease progresses enough in a given case, the nephrologist or other practitioner and the patient will have to decide what form of renal replacement therapy will be used to treat end-stage<unk>  disease<unk>  failure, typically stage 4 or 5 of chronic<unk>  disease). That will either be some form of dialysis, which can be done at least two different ways at varying frequencies and durations (whether it is done at home or in the clinic depends on the method used and the patient's stability and training) and eventually, if they are eligible because of the nature and severity of their condition and if a suitable match can be found, unilateral or bilateral<unk>  transplantation. A Cochrane Review study of autosomal dominant<unk>  made note of the fact that it is important at all times, while avoiding antibiotic resistance, to control infections of the cysts in the<unk> s, and if affected, the liver, when needed for a certain duration to combat infection, by using, "bacteriostatic and bacteriocidal drugs". Prognosis ADPKD individuals might have a normal life; conversely, ARPKD can cause<unk>  dysfunction and can lead to<unk>  failure by the age of 40–60. ADPKD1 and ADPKD2 are very different, in that ADPKD2 is much milder. Currently, there are no therapies proven effective to prevent the progression of ADPKD.
Polycystic kidney disease
Cystic kidney disease
Medullary cystic kidney disease
Medullary sponge kidney
Shunt nephritis
Glomerulocystic kidney disease
Page kidney
Focal proliferative nephritis